Latest revenue
$6.2M
as of 2026-03-31
Latest net income
$-50.0M
as of 2026-03-31
Net margin
-802.7%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.83B
- Enterprise value
- $1.83B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $40.22
- 52-wk low
- $9.09
- Beta
- —
- Shares out
- 62.3M
5-year trend
What this company does
Item 1. Business. Overview We are a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (“ASOs”) to selectively restore protein levels. Our first investigational, new medicine in development, zorevunersen (STK-001), is a potential disease modifying medicine that is in late-stage clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is characterized by frequent, prolonged and refractory seizures beginning…
AI summary unavailable — showing raw filing excerpt
Generated from STOK's filing dated 2026-03-16
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this annual report, including our consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that…
AI summary unavailable — showing raw filing excerpt
Generated from STOK's filing dated 2026-03-16
Profitability
Operating margin
-11.2%
96.0%Net margin
-3.7%
98.5%Return on equity
-2.0%
95.0%Return on assets
-1.6%
95.0%Leverage
Debt / equity
0.19×
0.8%Debt / assets
15.8%
0.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $6.2M | -96.1% | $-50.0M | -144.3% | -802.7% |
Q4 2025 2025-12-31 | $1.4M | -93.8% | $-57.9M | -452.7% | -4132.2% |
Q3 2025 2025-09-30 | $10.6M | +117.2% | $-38.3M | -45.1% | -360.7% |
Q2 2025 2025-06-30 | $13.8M | +186.0% | $-23.5M | +8.6% | -170.0% |
Q1 2025 2025-03-31 | $158.6M | +3661.1% | $112.9M | +528.0% | 71.2% |
Q4 2024 2024-12-31 | $22.6M | — | $-10.5M | — | -46.4% |
Q3 2024 2024-09-30 | $4.9M | +47.9% | $-26.4M | -7.7% | -540.0% |
Q2 2024 2024-06-30 | $4.8M | +294.7% | $-25.7M | +16.2% | -531.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on STOK — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$42.8M
Net activity
−$42.8M
Distinct insiders
9
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns STOK
Institutional value
$638.6M
Total shares held
19.7M
Distinct holders
98
-86 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.4M | $175.4M | +173.2K (+3.3%) | Added |
| 2 | Lynx1 Capital Management LP | 4.8M | $155.1M | -641.0K (-11.9%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | $76.7M | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 989.9K | $32.2M | +162.8K (+19.7%) | Added |
| 5 | Assenagon Asset Management S.A. | 907.0K | $29.5M | -320.7K (-26.1%) | Trimmed |
| 6 | BAILLIE GIFFORD & CO | 575.2K | $18.7M | +328.3K (+133.0%) | Added |
| 7 | Candriam S.C.A. | 502.0K | $16.3M | -391.4K (-43.8%) | Trimmed |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 462.7K | $15.1M | — | New |
| 9 | Erste Asset Management GmbH | 446.0K | $14.2M | +50.0K (+12.6%) | Added |
| 10 | VANGUARD FIDUCIARY TRUST CO | 356.9K | $11.6M | — | New |
| 11 | Artisan Partners Limited Partnership | 315.5K | $10.3M | — | New |
| 12 | JPMORGAN CHASE & CO | 265.5K | $8.4M | -12.5K (-4.5%) | Trimmed |
| 13 | FIRST TRUST ADVISORS LP | 163.5K | $5.3M | +780 (+0.5%) | Added |
| 14 | UBS Group AG | 158.3K | $5.2M | -11.4K (-6.7%) | Trimmed |
| 15 | Invesco Ltd. | 150.0K | $4.9M | -109.5K (-42.2%) | Trimmed |
| 16 | Bank of New York Mellon Corp | 143.4K | $4.7M | +2.6K (+1.9%) | Added |
| 17 | FRANKLIN RESOURCES INC | 142.8K | $4.6M | +10.6K (+8.0%) | Added |
| 18 | Nuveen, LLC | 108.6K | $3.5M | +4.4K (+4.2%) | Added |
| 19 | HUSSMAN STRATEGIC ADVISORS, INC. | 84.0K | $2.7M | +21.0K (+33.3%) | Added |
| 20 | Swiss National Bank | 79.1K | $2.6M | +3.4K (+4.5%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once STOK's latest filing finishes processing.